Sosei Group Corporation and Cancer Research UK announced the signing of an agreement to bring Sosei Heptares’ cancer immunotherapy drug candidate into a first-in-human trial.
[Sosei Group Corporation]
Home Newsletters Cell Therapy News Cancer Research UK and Sosei Heptares Sign Agreement to Advance Cancer Immunotherapy...
